HC Wainwright Has Bullish Estimate for CMPS FY2028 Earnings

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) – Stock analysts at HC Wainwright raised their FY2028 earnings per share estimates for Compass Pathways in a research report issued to clients and investors on Friday, May 15th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of $1.64 for the year, up from their previous estimate of $1.56. HC Wainwright currently has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for Compass Pathways’ current full-year earnings is ($0.97) per share. HC Wainwright also issued estimates for Compass Pathways’ FY2029 earnings at $3.78 EPS and FY2030 earnings at $6.59 EPS.

Other equities research analysts have also issued reports about the company. B. Riley Financial began coverage on Compass Pathways in a research note on Friday, April 24th. They set a “buy” rating and a $17.00 price target for the company. Lifesci Capital raised Compass Pathways to a “strong-buy” rating in a research report on Thursday, February 12th. Morgan Stanley lifted their target price on Compass Pathways from $16.00 to $17.00 and gave the company an “overweight” rating in a research report on Thursday, May 14th. Canaccord Genuity Group decreased their target price on Compass Pathways from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, March 26th. Finally, BTIG Research reaffirmed a “buy” rating and set a $14.00 target price on shares of Compass Pathways in a research report on Wednesday, May 13th. Two analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $20.58.

Compass Pathways Price Performance

Shares of Compass Pathways stock opened at $10.07 on Monday. Compass Pathways has a one year low of $2.25 and a one year high of $11.65. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.32 and a current ratio of 3.32. The stock has a market cap of $1.36 billion, a price-to-earnings ratio of -3.20 and a beta of 2.39. The stock has a 50 day moving average price of $7.37 and a 200-day moving average price of $6.80.

Compass Pathways (NASDAQ:CMPS) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.15.

Hedge Funds Weigh In On Compass Pathways

Institutional investors have recently made changes to their positions in the business. Toronto Dominion Bank grew its holdings in shares of Compass Pathways by 152.9% during the fourth quarter. Toronto Dominion Bank now owns 2,529,013 shares of the company’s stock valued at $17,447,000 after purchasing an additional 1,529,013 shares during the last quarter. Jefferies Financial Group Inc. acquired a new stake in shares of Compass Pathways during the 3rd quarter valued at $7,890,000. Nantahala Capital Management LLC lifted its holdings in shares of Compass Pathways by 47.7% in the second quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock valued at $11,704,000 after purchasing an additional 1,350,698 shares in the last quarter. Ameriprise Financial Inc. acquired a new position in shares of Compass Pathways in the third quarter worth $6,926,000. Finally, Orbimed Advisors LLC acquired a new stake in shares of Compass Pathways in the first quarter valued at about $6,363,000. 46.19% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Compass Pathways

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $70 price target on Compass Pathways while raising several earnings estimates for 2026–2027, signaling improving long-term expectations for the company. HC Wainwright estimate updates
• Positive Sentiment: Retail-focused headlines suggest traders are betting on a major FDA-related catalyst, which has helped fuel renewed momentum in the shares. CMPS stock breaking out again
• Positive Sentiment: Unusually heavy options activity on Monday showed strong speculative interest, with call buying running well above normal levels and reinforcing bullish sentiment. Options trading activity
• Neutral Sentiment: Additional coverage highlighted Compass Pathways as a “hot” psychedelics stock, reflecting strong trader enthusiasm but not adding new fundamental information. Psychedelics stock coverage
• Negative Sentiment: One research update from LifeSci Capital reportedly cut earnings estimates for Compass Pathways, which could temper enthusiasm if investors focus on execution risk and continued losses. LifeSci Capital cuts estimates

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.